Results 51 to 60 of about 487,050 (179)

Preclinical Target Animal Safety Evaluation of Veterinary Monoclonal Antibodies: Principles, Methods, and Interpretation

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT Monoclonal antibodies (mAbs) represent a rapidly expanding pharmaceutical class in veterinary medicine, with several products now authorized for use in dogs and cats. Limited published articles and veterinarian exposure to the principles of drug development present challenges in interpreting published safety evaluations that inform product ...
Adam Werts, Matthew Kuhn, Lauren Bessey, Alicia Braxton Hickman, Emily Chory, John Mitchell, Kirby Pasloske   +6 more
wiley   +1 more source

Discovery and characterization of single-domain antibodies for polymeric Ig receptor-mediated mucosal delivery of biologics

mAbs, 2020
Mucosal immunity is dominated by secretory IgA and IgM, although these are less favorable compared to IgG molecules for therapeutic development. Polymeric IgA and IgM are actively transported across the epithelial barrier via engagement of the polymeric ...
Bharathikumar Vellalore Maruthachalam, Adam Zwolak, Xiefan Lin-Schmidt, Edward Keough, Ninkka Tamot, Sathya Venkataramani, Brian Geist, Sanjaya Singh, Rajkumar Ganesan   +8 more
doaj   +1 more source

Beyond IgE: Expanding Perspectives on Multiclass Immunoglobulin Responses in Anisakis Allergy

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Anisakis allergy may involve antibody responses beyond IgE alone. Considering both mucosal and systemic immunoglobulin responses may improve our understanding of sensitization, immune regulation, and host–parasite interactions; although further studies are required before these observations can be translated into clinical practice.
Patpicha Arunsan, Nathkapach K. Rattanapitoon, Phornphitcha Pechdee, Schawanya K. Rattanapitoon   +3 more
wiley   +1 more source

Harnessing Natural Killer Cells: From Neuroimmunology to Novel Therapies for Central Nervous System Diseases

MedComm, Volume 7, Issue 10, October 2026.
This review delineates the multifaceted roles of natural killer (NK) cells in the central nervous system, spanning direct cytolysis, immunoregulation, and crosstalk with the brain microenvironment. We evaluate the translational potential and challenges of NK cell immunotherapies for a spectrum of neurological conditions.
Kaihang Deng, Wai Po Chong
wiley   +1 more source

Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions

mAbs
The development of bispecific antibodies that bind at least two different targets relies on bringing together multiple binding domains with different binding properties and biophysical characteristics to produce a drug-like therapeutic.
Michael Mullin, James McClory, Winston Haynes, Justin Grace, Nathan Robertson, Gino van Heeke   +5 more
doaj   +1 more source

Next generation of multispecific antibody engineering

Antibody Therapeutics, 2023
Abstract Multispecific antibodies recognize two or more epitopes located on the same or distinct targets. This added capability through protein design allows these man-made molecules to address unmet medical needs that are no longer possible with single targeting such as with monoclonal antibodies or cytokines alone.
Daniel Keri, Matt Walker, Isha Singh, Kyle Nishikawa, Fernando Garces   +4 more
openaire   +2 more sources

Guiding the development of multispecific antibody-based cancer immunotherapies with 89Zr-immuno-PET imaging [PDF]

Antibody-based checkpoint inhibitors improved the treatment of patients with several tumor types. Several antibodies targeting immune checkpoints have been approved for the treatment of patients with cancers.
van Winkel, Claudia; id_orcid
core   +1 more source

Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment

Frontiers in Immunology, 2022
Recombinant antibodies such as nanobodies are progressively demonstrating to be a valid alternative to conventional monoclonal antibodies also for clinical applications. Furthermore, they do not solely represent a substitute for monoclonal antibodies but
Jiewen Wang, Jiewen Wang, Jiewen Wang, Guangbo Kang, Guangbo Kang, Guangbo Kang, Haibin Yuan, Haibin Yuan, Haibin Yuan, Xiaocang Cao, He Huang, He Huang, He Huang, Ario de Marco   +13 more
doaj   +1 more source

Natural Killer Cells in Paediatric Soft Tissue Sarcomas: A Systematic Review

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Paediatric soft tissue sarcomas (pSTS) are a rare and heterogeneous group of malignant tumours arising in tissues of mesenchymal origin. The role of natural killer (NK) cells in pSTS remains poorly understood, with evidence fragmented across small preclinical studies and early‐phase clinical trials.
Raya Dean, Lara V. Graham, Christina Putnam, Rosa Gomes Alves Martins, Daniel T. Harding, Tim J. Underwood, Zoë S. Walters, Matthew D. Blunt   +7 more
wiley   +1 more source

Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders

Advanced Science, Volume 13, Issue 50, 7 September 2026.
Antibody can be engineered into diverse lysosome‐targeting chimeras that convert target recognition into active degradation. By coupling antibody binding with recruited receptors, encoded domains, conjugated ligands, or nanoparticle scaffolds, these antibody‐associated targeted chimeras (AbTACs) platforms direct extracellular and membrane proteins ...
Kaige Chen, Quanyin Hu
wiley   +1 more source